Dechra Pharmaceuticals PLC
LSE:DPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 856
3 866
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC
Current Portion of Long-Term Debt
Dechra Pharmaceuticals PLC
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Current Portion of Long-Term Debt
£3.9m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
27%
|
CAGR 10-Years
-9%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Current Portion of Long-Term Debt
£3.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Current Portion of Long-Term Debt
$2.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Current Portion of Long-Term Debt
$13m
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Current Portion of Long-Term Debt
$136m
|
CAGR 3-Years
41%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
8%
|
|
Dechra Pharmaceuticals PLC
Glance View
Dechra Pharmaceuticals PLC has carved out its niche in the veterinary pharmaceuticals industry, focusing on animal health, which is a sector often less spotlighted than its human counterpart but equally vital. Established in 1997 and headquartered in Northwich, Cheshire, England, Dechra has steadily made a name for itself as a formidable player addressing veterinary needs through innovative solutions and a dedication to expanding its product range. This company has built its empire by developing, manufacturing, and selling high-quality products that cater to the health of both companion animals, such as dogs and cats, and livestock. They have embedded themselves deeply into the global market, with a presence in countries across Europe, North America, and other regions, addressing therapeutic areas like endocrinology, dermatology, and anesthetics. A significant proportion of Dechra’s revenue comes through their strong partnerships and customer base spread across various veterinary practices and pet owners who rely on their trusted brands like Vetoryl and Felimazole. The company’s business model is finely tuned with a blend of regular product launches and strategic acquisitions, creating a comprehensive portfolio that keeps them ahead in the innovation curve. Not only do they supply medicine, but Dechra also invests heavily in research and development to ensure their offerings remain at the forefront of veterinary medicine. Through this, they balance between organic growth and strategic acquisitions, effectively broadening their impact in the field. This approach has not only propelled their financial success but also underscored their commitment to enhancing the welfare of animals globally.
See Also
What is Dechra Pharmaceuticals PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
3.9m
GBP
Based on the financial report for Jun 30, 2023, Dechra Pharmaceuticals PLC's Current Portion of Long-Term Debt amounts to 3.9m GBP.
What is Dechra Pharmaceuticals PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-9%
Over the last year, the Current Portion of Long-Term Debt growth was 18%. The average annual Current Portion of Long-Term Debt growth rates for Dechra Pharmaceuticals PLC have been -5% over the past three years , 27% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet
